Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study

[1]  Philippa J Easterbrook,et al.  Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis. , 2023, The lancet. Gastroenterology & hepatology.

[2]  J. Ward,et al.  Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis. , 2022, The International journal on drug policy.

[3]  M. Manns,et al.  Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study , 2022, JHEP reports : innovation in hepatology.

[4]  Jisoo A. Kwon,et al.  Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. , 2022, The lancet. Gastroenterology & hepatology.

[5]  P. Read,et al.  Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. , 2021, Journal of hepatology.

[6]  F. Luciani,et al.  Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis , 2020, Nature Communications.

[7]  C. Boesecke.  Recently acquired and early chronic hepatitis C in men having sex with men (MSM): Recommendations from the NEAT-ID consensus panel. , 2020, AIDS.

[8]  G. Cooke,et al.  Short‐Duration Pan‐Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection , 2020, Hepatology.

[9]  Y. Yazdanpanah,et al.  Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM. , 2020, The Journal of antimicrobial chemotherapy.

[10]  A. Lok,et al.  Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy. , 2019, Gastroenterology.

[11]  G. Lauer,et al.  Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. , 2019, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[12]  W. Bierman,et al.  Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. , 2019, The lancet. Gastroenterology & hepatology.

[13]  M. Hughes,et al.  Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  G. Cooke,et al.  Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection , 2018, Journal of viral hepatitis.

[15]  G. Dore,et al.  Management of acute HCV infection in the era of direct-acting antiviral therapy , 2018, Nature Reviews Gastroenterology & Hepatology.

[16]  O. Weiland,et al.  Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. , 2018, Journal of hepatology.

[17]  J. Chhatwal,et al.  Should we treat acute hepatitis C? A decision and cost‐effectiveness analysis , 2018, Hepatology.

[18]  T. Asselah,et al.  Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection , 2018, The New England journal of medicine.

[19]  M. Manns,et al.  Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection , 2017, The New England journal of medicine.

[20]  J. Rockstroh,et al.  Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. , 2017, The lancet. Gastroenterology & hepatology.

[21]  M. Manns,et al.  Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. , 2017, The Lancet. Infectious diseases.

[22]  A. Howe,et al.  Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial , 2017, Hepatology.

[23]  M. Hellard,et al.  Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study , 2016, Hepatology.

[24]  H. Dahari,et al.  HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. , 2016, Journal of hepatology.

[25]  Thomas Lengauer,et al.  Geno2pheno[HCV] – A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents , 2016, PloS one.

[26]  T. Asselah,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.

[27]  G. Dore,et al.  The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis , 2015, PloS one.

[28]  G. Dore,et al.  Case definitions for acute hepatitis C virus infection: a systematic review. , 2012, Journal of hepatology.

[29]  Tommy F. Liu,et al.  Automating HIV Drug Resistance Genotyping with RECall, a Freely Accessible Sequence Analysis Tool , 2012, Journal of Clinical Microbiology.

[30]  M. Fisher.  Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. , 2011, AIDS.

[31]  Wolters Kluwer.  Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel European Treatment Network for HIV, Hepatitis and Global Infectious Diseases (NEAT-ID) Consensus Panel , 2020 .